A recent prospective follow-up study showed that fluvoxamine significantly reduced interleukin-6 levels in major depressive disorder patients with high IL-6 baseline levels, indicating that the SSRI might be useful for patients with inflammatory depression, a subtype of depression featured by high incidence of treatment resistance [118,119]. This evidence concerns the gene IL6 and depressive symptom measurement.